The multivariate analysis supported the association observed in the univariate analysis for inferior clinical outcomes in myeloma patients carrying PPM1D gene mutations treated with HDCT/ASCT, for example, in PFS time with a hazard ratio of 6.4 (p = 0.002) and in OS time with a hazard ratio of 8 (p = 0.004) (Table 4). This evidence concerns the gene PPM1D and plasma cell myeloma.